OsteoGuard – Clinical Performance

Phase 1 identified that **16.35% of the study sample were at high bone-health risk but were not captured by current age-based screening criteria,** revealing a sizable group of individuals who could benefit from earlier evaluation and intervention. This "missed high-risk" cohort forms the basis for simulating OsteoGuard's clinical impact and demonstrates the potential value of enhanced screening combined with targeted treatment.

⚠ Phase 1

MISSED HIGH RISK
16.35%
of study sample identified as missed high risk

15.22% after adjusting for survey strata, PSU, and sample weights.

📈 24 mo

HIGH ADHERENCE
+5.36%
spine BMD improvement

✓ Groups

REMAINING GROUPS
Moderate:	+3.44%
Poor:	+1.60%
Control:	−1.55%
Discontinued:	+1.07%

🛡 Efficacy

FRACTURE RISK INCIDENCE
6.7% vs 12.6%
treatment vs control

Lumbar Spine BMD at Baseline and 24 Months by Adherence Group

Adherence Group	Baseline BMD (g/cm²)	Baseline SD	24-Month BMD (g/cm²)	24-Month SD	Percent Change (%)	n
Control	0.858	0.067	0.845	0.066	-1.552	254
Poor	0.867	0.073	0.881	0.076	1.604	39
Moderate	0.857	0.073	0.887	0.076	3.439	62
High	0.846	0.068	0.892	0.072	5.359	87
Discontinued	0.855	0.065	0.864	0.067	1.073	66

Lumbar Spine BMD: Baseline vs 24 Months

Baseline ■ 24 Months

	Control	Poor	Moderate	High	Discontinued
	0.858 0.845	0.867 0.881	0.857 0.887	0.846 0.892	0.855 0.864
	−1.55%	+1.60%	+3.44%	+5.36%	+1.07%

BMD density in g/cm² • All values from actual trial data

Fracture Incidence by Treatment Group

Control: 12.6%
Treatment: 6.7%

(Proportion vs Group)

Key Takeaways

Adherence Drives Efficacy
Good adherence to medication improved bone density by 5.36% in high adherence groups over 24 months, demonstrating direct treatment benefit.

Fracture Risk Reduction
Treatment reduces fracture incidence to 6.7% vs 12.6% in control, representing a 46.8% relative risk reduction in major osteoporotic fractures.

Missed High-Risk Opportunity
16.35% of Phase 1 sample were identified as missed high-risk patients, highlighting untreated osteoporosis burden in the population.

Global Impact Potential
Improved identification and treatment of high-risk populations could substantially reduce osteoporosis-related fractures globally and improve patient outcomes.

OsteoGuard – Commercial Performance

TREATMENT PRICE/MO

$10.49
Per patient monthly

PROFIT/PATIENT/MO

$9.45
90% margin

AVG TREATMENT

60
Months duration

CAC:LTV RATIO

## 5.67x
Strong unit economics

Financial Growth Trajectory
Revenue, Profit & Cost over 60 months

● Revenue ● Profit ● Cost

- $3.0M
- $2.5M
- $2.0M
- $1.5M
- $1.0M
- $500K

-$564K loss

Breakeven

$2.56M profit

Amount ($)

M1 M12 M24 M36 M48 M60

Breakeven (M24)

Treatment Timeline (Months)

Unit Economics

PARAMETER	VALUE ($)
Monthly revenue per patient	10.49
Monthly mfg/distribution cost per patient	1.04
Monthly profit per patient	9.45

Financial Summary

METRIC	VALUE
Customer Acquisition Cost (CAC)	$100.00
Profit per Patient per Month	$9.45
Average Treatment Duration	60 months
Lifetime Value (LTV)	$567.00
CAC:LTV Ratio	5.67x

Key Takeaways:
- Large missed high-risk group (estimated 15.22% of U.S. adult population)   •   High CAC:LTV – $100:$567 - 5.67x